Boston Scientific - On Demand

Join the SMARTT Y90 Programme 2024: A Leap Forward in HCC Treatment

Embark on the new SMARTT Y90 Programme 2024

Learn how TheraSphere Y-90 Therapy preserves liver function while achieving tumour response.
Embark now on the first Live Workshop

Evolving Multidisciplinary Treatment Strategies in
Primary Liver Tumours

June 12^th | 5 PM CET

Faculty

Dr. Sherrie Bhoori
Hepatologist
Milan, IT

Prof. Eric Vibert
Liver Transplant Surgeon
Villejuif, FR

Dr. David Pinato
Medical Oncologist
London, UK

Prof. Boris Guiu
Interventional Radiologist
Montpellier, FR

Prof. Etienne Garin
Nuclear Medicine Physician
Rennes, FR

Agenda

Improving survival in primary liver cancer: treatment strategies with TheraSphere Y-90 Therapy | Prof. Guiu.
Curative Surgery and Locoregional Neoadjuvant Therapies in HCC | Prof. Vibert.
SIRT Treatment approach in downstaging HCC and the impact on clinical outcomes | Prof. Garin.
Multidisciplinary treatment strategies for HCC – the medical oncologist perspective | Dr. Pinato.

Join the Workshop

Discover the SMARTT Y90 Programme 2024 with renown liver cancer specialists to together redefine patient outcomes.

Boston Scientific International SA

www.bostonscientific.eu | Tel: +33 1 39 30 97 00

Parc Val Saint Quentin - Bâtiment H | 2 Rue René Caudron | 78960 Voisins-le-Bretonneux

VAT: FR07420668402

CAUTION

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.

PI-1853902-AA

Privacy Policy | Terms of Use

For questions on privacy
Contact our EU Data Protection Officer at: [email protected]
Boston Scientific
c/Ribera del Loira, 46 Edificio 2
28042 Madrid (Spain)